Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.
Biomedical Research Institute, Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.
Eur J Heart Fail. 2021 Jun;23(6):954-963. doi: 10.1002/ejhf.2142. Epub 2021 Mar 9.
To investigate the prognostic value of diagnostic scores for heart failure (HF) with preserved ejection fraction (HFpEF).
Consecutive patients with HFpEF admitted for unequivocal decompensated HF treated with intravenous loop diuretics were evaluated (n = 443; mean age 78 ± 12 years; 60% women). The HFA-PEFF and H FPEF scores were calculated for all patients with echocardiography data available within 1 year and the population was stratified according to HFA-PEFF scores 2-4 (n = 79), 5 (n = 93), or 6 (n = 271) and H FPEF score probabilities <90% (n = 80), 90-95% (n = 61), and 96-100% (n = 293). HF readmission rates (95% confidence intervals) increased from 28.9 (22.7-35.0) per 100 patient-years in HFA-PEFF 2-4 to 46.0 (38.5-53.5) in HFA-PEFF 5 and 45.0 (40.1-49.8) in HFA-PEFF 6. Similarly, HF readmission rates increased with increasing H FPEF probability: <0.90 [31.8 (25.3-38.2) per 100 patient-years], 0.90-0.95 [41.5 (32.9-50.1)], and 0.96-1.00 [45.9 (41.2-50.6]. Median survival was 65 months (36-89 months) in HFA-PEFF score 2-4, 45 months (26-59 months) in HFA-PEFF score 5, and 28 months (22-42 months) in HFA-PEFF score 6 (P < 0.001), while the hazard ratio (95% confidence interval) for all-cause mortality was 1.16 (1.02-1.32) per 0.10 increase in H FPEF probability.
Among patients hospitalized with HFpEF, higher HFpEF probability according to diagnostic scores is associated with increased risk of subsequent HF readmissions and all-cause mortality.
探讨诊断评分对射血分数保留的心力衰竭(HFpEF)的预后价值。
连续入选因明确失代偿性 HF 而接受静脉袢利尿剂治疗的 HFpEF 患者(n=443;平均年龄 78±12 岁;60%为女性)。对所有在 1 年内有超声心动图数据的患者计算 HFA-PEFF 和 HFpEF 评分,并根据 HFA-PEFF 评分 2-4(n=79)、5(n=93)或 6(n=271)和 HFpEF 评分概率<90%(n=80)、90-95%(n=61)和 96-100%(n=293)对人群进行分层。HF 再入院率(95%置信区间)从 HFA-PEFF 2-4 组的 28.9(22.7-35.0)/100 患者-年增加至 HFA-PEFF 5 组的 46.0(38.5-53.5)和 HFA-PEFF 6 组的 45.0(40.1-49.8)。同样,HF 再入院率随着 HFpEF 概率的增加而增加:<0.90[31.8(25.3-38.2)/100 患者-年]、0.90-0.95[41.5(32.9-50.1)]和 0.96-1.00[45.9(41.2-50.6)]。HFA-PEFF 评分 2-4 组的中位生存时间为 65 个月(36-89 个月),HFA-PEFF 评分 5 组为 45 个月(26-59 个月),HFA-PEFF 评分 6 组为 28 个月(22-42 个月)(P<0.001),而 HFpEF 概率每增加 0.10,全因死亡率的风险比(95%置信区间)为 1.16(1.02-1.32)。
在因 HFpEF 住院的患者中,根据诊断评分的 HFpEF 概率较高与随后 HF 再入院和全因死亡率增加相关。